Related Experiment Videos
Uptake of 99mTc-phytate in osteosarcoma cases
P N Rao1, S N Murthy, S Devaru
1Department of Nuclear Medicine, Kidwai Memorial Institute of Oncology, Bangalore, India.
European Journal of Nuclear Medicine
|January 1, 1989
Summary
Unusual uptake of technetium-99m phytate (99mTc-phytate) was observed at osteosarcoma primary tumor sites during routine scintigraphy. This finding was persistent and not seen with technetium-99m sulfur colloid, suggesting a specific interaction.
Area of Science:
- Nuclear medicine
- Oncology
- Radiopharmacology
Background:
- Liver spleen scintigraphy is a routine diagnostic procedure.
- Osteosarcoma is a primary bone cancer.
- 99mTc-phytate is a radiopharmaceutical used in scintigraphy.
Observation:
- An unusual uptake of 99mTc-phytate was noted at the primary osteosarcoma site in five patients.
- This uptake was persistent on both early and delayed imaging.
- 99mTc-sulfur colloid did not show uptake at the tumor site in one patient.
Findings:
- 99mTc-phytate demonstrates specific uptake in osteosarcoma primary tumors.
- The mechanism of uptake is distinct from that of 99mTc-sulfur colloid.
- This suggests a potential role for 99mTc-phytate in osteosarcoma imaging.
Implications:
- This observation may lead to new diagnostic applications for 99mTc-phytate in osteosarcoma.
- Further research is warranted to elucidate the mechanism of 99mTc-phytate uptake in osteosarcoma.
- This could potentially improve the characterization and detection of primary osteosarcoma lesions.